Tag Archives: Targeted protein degradation

Targeted Protein Degradation: The First Proof-of-Mechanism in a Randomized, Placebo-Controlled Study
July 6, 2021

By Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera Therapeutics, as part of the From The Trenches feature of LifeSciVC. The inherent ability to combine the power of genetic-like knockdown with the flexibility of small molecules; the power to

Leave a comment

Drugging The Undruggable: Kymera’s Targeted Protein Degradation
October 30, 2017

The term “undruggable” has entered common industry vernacular over the past two decades to describe biologic targets that couldn’t be addressed via narrow conventional pharmacologies involving catalytic-site inhibitors and antibodies. The “druggable genome” historically included intracellular catalytic proteins, (e.g., enzymes

Leave a comment